Digitalizing and Upgrading Severe Acute Respiratory Infections Surveillance in Malta: System Development

Background In late 2020, the European Centre for Disease Prevention and Control and Epiconcept started implementing a surveillance system for severe acute respiratory infections (SARI) across Europe. Objective We sought to describe the process of digitizing and upgrading SARI surveillance in Malta, an island country with a centralized health system, during the COVID-19 pandemic from February to November 2021. We described the characteristics of people included in the surveillance system and compared different SARI case definitions, including their advantages and disadvantages. This study also discusses the process, output, and future for SARI and other public health surveillance opportunities. Methods Malta has one main public hospital where, on admission, patient data are entered into electronic records as free text. Symptoms and comorbidities are manually extracted from these records, whereas other data are collected from registers. Collected data are formatted to produce weekly and monthly reports to inform public health actions. From October 2020 to February 2021, we established an analogue incidence-based system for SARI surveillance. From February 2021 onward, we mapped key stakeholders and digitized most surveillance processes. Results By November 30, 2021, 903 SARI cases were reported, with 380 (42.1%) positive for SARS-CoV-2. Of all SARI hospitalizations, 69 (7.6%) were admitted to the intensive care unit, 769 (85.2%) were discharged, 27 (3%) are still being treated, and 107 (11.8%) died. Among the 107 patients who died, 96 (89.7%) had more than one underlying condition, the most common of which were hypertension (n=57, 53.3%) and chronic heart disease (n=49, 45.8%). Conclusions The implementation of enhanced SARI surveillance in Malta was completed by the end of May 2021, allowing the monitoring of SARI incidence and patient characteristics. A future shift to register-based surveillance should improve SARI detection through automated processes.

[1]  S. de Lusignan,et al.  Vaccine effectiveness against symptomatic SARS-CoV-2 infection in adults aged 65 years and older in primary care: I-MOVE-COVID-19 project, Europe, December 2020 to May 2021 , 2021, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[2]  Karl Erik Müller,et al.  COVID-19 symptoms at hospital admission vary with age and sex: results from the ISARIC prospective multinational observational study , 2021, Infection.

[3]  Shubhabrata Mukherjee,et al.  Is COVID-19 Gender-sensitive? , 2021, Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology.

[4]  Kasen L. Culler,et al.  Dynamic Public Health Surveillance to Track and Mitigate the US COVID-19 Epidemic: Longitudinal Trend Analysis Study , 2020 .

[5]  E. Sapey,et al.  COVID-19: to be or not to be; that is the diagnostic question , 2020, Postgraduate Medical Journal.

[6]  W. van der Hoek,et al.  Experience of establishing severe acute respiratory surveillance in the Netherlands: Evaluation and challenges , 2020, Public Health in Practice.

[7]  De-Min Han,et al.  Gender Differences in Patients With COVID-19: Focus on Severity and Mortality , 2020, Frontiers in Public Health.

[8]  W. Haas,et al.  Establishing an ICD-10 code based SARI-surveillance in Germany – description of the system and first results from five recent influenza seasons , 2017, BMC Public Health.

[9]  U. Buchholz,et al.  Influenza vaccine effectiveness estimates in Europe in a season with three influenza type/subtypes circulating: the I-MOVE multicentre case-control study, influenza season 2012/13. , 2014, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[10]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[11]  R. Evans European Centre for Disease Prevention and Control. , 2014, Nursing standard (Royal College of Nursing (Great Britain) : 1987).

[12]  M. Valenciano,et al.  I-MOVE: a European network to measure the effectiveness of influenza vaccines. , 2012, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[13]  D. Heymann,et al.  Public health surveillance , 2011 .

[14]  S. Thacker,et al.  Planning a public health surveillance system. , 1995, Epidemiological bulletin.

[15]  A. Carter,et al.  Public health surveillance: historical origins, methods and evaluation. , 1994, Bulletin of the World Health Organization.